Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade.
A new analysis found that patients with multiple myeloma receiving standard therapies have much worse outcomes compared with those treated in clinical trials.
An exploratory analysis reveals potential associations between a dietary intervention and both a reduction in postmenopausal vasomotor symptoms and changes in the gut microbiome.
Benefits of genetic testing in adults with unexplained epilepsy include enrollment in a clinical trial of a relevant gene therapy, connection to families with a similar diagnosis, and peace of mind.